B12, HCG and allergy shots given at home or in a wellness clinic, where the monitoring that makes them defensible in a clinical setting is absent.
Most commercially available B12 injection vials (the kind sold online, prescribed by telehealth providers, and now widely self-administered at home) are multi-dose vials. Multi-dose vials require an antimicrobial preservative because they are punctured repeatedly. The standard preservative is benzyl alcohol, typically at 0.9%, the same CNS toxicant listed as a Proposition 65 reproductive toxicant that appears in IV Myers cocktail vials. In clinical IV settings, benzyl alcohol toxicity is a documented risk that triggered regulatory warnings and reformulation of neonatal products after a cluster of infant deaths. When the same compound is injected intramuscularly at home by a person who read about B12 on a wellness blog, the exposure is not managed, not tracked, and not connected to the neurological, hepatic, or reproductive consequences if they develop weeks or months later.
Benzyl alcohol is metabolized to benzaldehyde, then to benzoic acid, which is conjugated with glycine to form hippuric acid for renal excretion. This pathway requires glycine, an amino acid that competes with other detoxification demands. Repeated weekly injections in a person with compromised glycine availability (common in chronic illness, high toxic load, poor protein intake) produces benzaldehyde accumulation, a neurotoxic aldehyde. The person attributing their brain fog to B12 deficiency may be accumulating a neurotoxin from the preservative in the treatment.
Multi-dose vial stoppers are made from bromobutyl or chlorobutyl rubber compounds that contain aluminum-based vulcanization agents. Each time a needle punctures the stopper, it cores a microscopic plug of rubber containing aluminum residues into the solution. This is not a theoretical contamination pathway. It is a documented one in pharmaceutical literature on parenteral product safety. The first draw from a fresh vial introduces rubber particulates. The fifth draw from the same vial introduces more, from a stopper increasingly degraded by repeated puncture. Home users are not told to discard vials after a certain number of uses. The stopper degradation is invisible. The aluminum dose with each injection is small and unmeasured, and it accumulates, because aluminum is not efficiently excreted. It deposits in bone, brain, and liver. There is no monitoring. There is no threshold below which the accumulation is guaranteed harmless.
The B12 in the majority of injectable B12 products is cyanocobalamin, not the active form methylcobalamin or adenosylcobalamin. Cyanocobalamin is synthetic. It contains a cyanide group (CN⁻) bound to the cobalt atom. Before the body can use it, the liver must cleave the cyanide molecule, detoxify and excrete it, and then convert the remaining cobalamin to the active methylated or adenosyl form. This conversion requires adequate MTHFR function, adequate methyl donors, and a functioning liver. The people most aggressively pursuing B12 injections are frequently those with MTHFR variants, chronic illness with compromised methylation, and elevated toxic load already burdening hepatic detoxification. They are the least equipped to handle cyanocobalamin and the most likely to be getting it. The cyanide load from a weekly cyanocobalamin injection is small in isolation. In a person with already-impaired detoxification and weekly exposure over months, it is not trivial.
High-dose injectable B12 elevates serum B12, which is what the blood test measures. A serum B12 level in the normal or high range does not mean the body is using B12 effectively. It means B12 is in circulation. Functional B12 deficiency, where B12 is present but methylation is impaired, is not detected by serum B12. More critically, flooding the system with B12 via injection drives the methyl cycle faster: consuming folate, methionine, and SAM-e (S-adenosylmethionine) in the process. In a person with marginal folate status (common in anyone eating processed, folic-acid-fortified food who cannot convert it) or MTHFR-impaired folate metabolism, driving B12 supplementation hard depletes the folate cofactors that B12 requires. Serum B12 rises. Functional methylation worsens. The person feels they need more B12 injections. The deficiency being treated is now the deficiency being created.
Intramuscular injection technique matters. Injection into the wrong plane (subcutaneous instead of intramuscular, or hitting a nerve or vessel) produces a different absorption profile, local tissue damage, and in the case of vessel injection, direct systemic delivery of benzyl alcohol and aluminum at higher speed than the IM route intended. Home users are typically self-taught from YouTube videos. They are injecting a pharmaceutical preparation into their own muscle, weekly, without the training, anatomical knowledge, or supervision that clinical injection practice requires. Needle reuse, common among home users trying to extend a supply, introduces additional particulate contamination into already-degraded multi-dose vials. The sterile field that a clinical setting provides is recreated at a kitchen table. The consequences of technique failure (abscess, nerve damage, particulate embolism from rubber stopper coring) are not listed on the wellness influencer's reel recommending the practice.
Human chorionic gonadotropin (HCG) is a hormone produced by the developing placenta beginning days after fertilization. Its biological purpose is singular and critical: it signals the corpus luteum to continue producing progesterone, preventing menstruation and maintaining the uterine lining long enough for the embryo to implant and the placenta to establish itself. It is a pregnancy survival signal. The body makes it in large quantities during the first trimester. It is the hormone detected by pregnancy tests. Outside of pregnancy, it is produced in meaningful amounts only by certain tumors (choriocarcinoma, testicular cancer, some ovarian cancers), which is why a positive HCG in a non-pregnant person is a cancer flag. This is the hormone being injected for weight loss, "metabolic reset," and "hormonal optimization" in wellness clinics and at home.
The Simeons protocol, developed in the 1950s, pairs daily HCG injections with a 500-calorie-per-day diet. The claim is that HCG mobilizes stored fat for fuel, suppressing hunger and sparing muscle while the extreme caloric restriction drives weight loss. Every randomized controlled trial that has tested this has found no difference between HCG and saline placebo when both groups eat 500 calories per day. The weight loss is entirely from 500-calorie starvation, which would produce weight loss with or without the injection. The FDA and FTC have both explicitly stated that HCG weight loss products are fraudulent and that homeopathic HCG (the over-the-counter version widely sold online) is not HCG at all. It contains no measurable HCG. The 500-calorie protocol is clinically dangerous: it produces severe muscle loss, micronutrient deficiency, gallstone formation (rapid weight loss is a primary driver of gallstone disease), electrolyte imbalance, cardiac arrhythmia, and profound metabolic disruption. Starvation at 500 calories is not a treatment. It is the harm.
In 2020, the FDA effectively ended the use of compounded HCG for weight loss by removing it from the list of bulk drug substances that compounding pharmacies may use. Pharmaceutical HCG (Pregnyl, Novarel, Ovidrel) is a controlled prescription hormone approved only for specific fertility indications: ovulation induction, treatment of anovulation, and in males, hypogonadotropic hypogonadism and cryptorchidism. It is not approved for weight loss, metabolic optimization, or anti-aging. Wellness clinics and telehealth providers continue to prescribe compounded or pharmaceutical HCG off-label for these unapproved uses. The person receiving it is not being told they are receiving a banned compounded substance or a fertility hormone used entirely outside its approved indication.
HCG binds to LH (luteinizing hormone) receptors: in women, in the ovary; in men, in the Leydig cells of the testes. In women, supraphysiological HCG stimulation outside of a clinically managed fertility cycle carries the risk of ovarian hyperstimulation syndrome (OHSS): the ovaries swell, fluid shifts into the abdomen and chest, causing bloating, pain, nausea, and in severe cases, thromboembolism, renal failure, and death. OHSS is a known complication of fertility treatment managed by specialists with ultrasound monitoring and dose titration. In a wellness context, no monitoring is performed and the risk is not disclosed.
In men, HCG is used in testosterone replacement therapy to maintain testicular volume and endogenous testosterone production, because exogenous testosterone suppresses the HPG axis and causes testicular atrophy. HCG mimics LH and keeps the Leydig cells active. This is a legitimate clinical use. The risks in that context include LH receptor desensitization with chronic high-dose HCG (the receptors downregulate, and endogenous LH signaling becomes less effective even after stopping), gynecomastia from aromatization of HCG-stimulated testosterone to estradiol, acne, erythrocytosis, and mood instability. These are risks managed by prescribers who monitor estradiol and hematocrit. They are not managed in a "testosterone optimization" wellness subscription.
HCG also has weak thyroid-stimulating activity, it shares structural homology with TSH. At high doses (as seen in first-trimester pregnancy and in HCG-secreting tumors), it causes transient hyperthyroidism. Wellness doses are lower, but thyroid stimulation in a person with undiagnosed thyroid nodules or subclinical Graves' disease is not a neutral event.
Pharmaceutical HCG multi-dose vials use the same benzyl alcohol preservative system as B12 injections. The rubber stopper aluminum contamination pathway is identical. The injection technique risks (wrong plane, vessel injection, infection, particulate contamination from stopper coring) are the same. What is different is what is being injected: not a vitamin, but a signaling hormone that directly activates gonadal receptors, modulates the hypothalamic-pituitary-gonadal axis, and stimulates thyroid. The downstream consequences of repeated low-grade hormone receptor activation from impure, incorrectly administered, unmonitored exogenous HCG are not studied in the wellness context because the wellness context is not studied. The fertility literature documents what goes wrong under clinical conditions with trained staff and monitoring. What goes wrong at home, unmonitored, in a person whose hormonal baseline was never established, is not in the literature. It is in the patient's body.
HCG stimulates estrogen production (via ovarian stimulation in women and aromatization in men). Elevated estrogen is a pro-coagulant state. It increases clotting factor synthesis and platelet aggregation. First-trimester pregnancy, when HCG is highest, is a known elevated thromboembolism period. OHSS carries significant thromboembolism risk: deep vein thrombosis, pulmonary embolism, and arterial thrombosis have all been reported as direct OHSS complications. A person receiving HCG injections for weight loss or metabolic optimization without any assessment of thrombophilia risk factors (Factor V Leiden, prothrombin mutation, antiphospholipid antibodies, personal or family history of clotting events) is receiving an estrogenic pro-coagulant stimulus with no safety net. The wellness practitioner prescribing it did not run a thrombophilia panel. The person did not know to ask.
Subcutaneous allergy immunotherapy (allergy shots) delivers diluted allergen extracts over years to desensitize the immune system. The mechanism has clinical support. What is less discussed is what the extracts are prepared in. Standard allergen extract vials contain phenol as a preservative (typically 0.4%) and many formulations contain aluminum hydroxide (alum) as an adjuvant to amplify immune response. Phenol is injected subcutaneously at every session. Aluminum accumulates with each injection. Neither is mentioned in the consent process for most allergy practices. The person is focused on the allergen. The vehicle is invisible.
Allergy shots require a mandatory 30-minute monitored wait after each injection because anaphylaxis is a known risk, including fatal anaphylaxis. This is not a precaution for rare circumstances. It is a standard protocol because the reaction rate is clinically significant. Every injection carries this risk. Over a 3–5 year course of weekly injections, the cumulative phenol and aluminum load is substantial, and the cumulative anaphylaxis risk is never framed as a reason to evaluate whether the course of treatment is proportionate to the clinical benefit.